Literature DB >> 26614515

Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response.

Alessia Pellerino1, Riccardo Soffietti2, Roberta Rudà2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26614515     DOI: 10.1007/s11060-015-2016-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  2 in total

1.  Methylation of O6-methyl guanine methyltransferase gene promoter in meningiomas--comparison between tumor grades I, II, and III.

Authors:  Leila Larijani; Zahra Madjd; Ali Samadikuchaksaraei; Shima Younespour; Hanieh Zham; Azadeh Rakhshan; Foruzan Mohammadi; Ali Rahbari; Afshin Moradi
Journal:  Asian Pac J Cancer Prev       Date:  2014

2.  Temozolomide for treatment-resistant recurrent meningioma.

Authors:  Marc C Chamberlain; Denice D Tsao-Wei; Susan Groshen
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

  2 in total
  3 in total

1.  Case Report: Identification of a Novel GNAS Mutation and 1p/22q Co-Deletion in a Patient With Multiple Recurrent Meningiomas Sensitive to Sunitinib.

Authors:  Weiping Hong; Changguo Shan; Minting Ye; Yanying Yang; Hui Wang; Furong Du; Xing Zhang; Chao Song; Linbo Cai
Journal:  Front Oncol       Date:  2021-10-15       Impact factor: 6.244

2.  Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.

Authors:  Katherine Belanger; Timothy H Ung; Denise Damek; Kevin O Lillehei; D Ryan Ormond
Journal:  BMC Cancer       Date:  2022-04-07       Impact factor: 4.430

3.  Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.

Authors:  Emily J Tonogai; Shan Huang; Rachel C Botham; Matthew R Berry; Stephen K Joslyn; Gregory B Daniel; Zixin Chen; Jianghong Rao; Xiang Zhang; Falguni Basuli; John H Rossmeisl; Gregory J Riggins; Amy K LeBlanc; Timothy M Fan; Paul J Hergenrother
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.